Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046924 | 0.93 | DPP4 (0.52) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL1567126 | 0.81 | DPP4 (0.56) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL7194801 | 0.81 | CD274 (0.69) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL31261742 | 0.80 | DPP4 (0.60) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL328862 | 0.80 | DPP4 (0.60) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL6968676 | 0.80 | DPP4 (0.60) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL2841431 | 0.79 | DPP4 (0.65) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL11333152 | 0.79 | DPP4 (0.65) | DPP4KMT2AFOLH1PDCD1CD274 | |
| SCHEMBL31387875 | 0.79 | DPP4 (0.65) | DPP4KMT2AFOLH1PDCD1CD274 | |
| Ethane SCHEMBL3681665 | 0.78 | DPP4 (0.58) | DPP4KMT2AFOLH1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209558-A | Use of Mpro protein inhibitors in medicaments for the treatment of novel coronavirus infections | 北京大学深圳研究生院 | 2023-12-12 | — | — | CN | claimed |
| JP-4537315-B2 | — | — | 2010-09-01 | — | — | JP | claimed |
| US-7741520-B2 | Sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-06-22 | — | — | US | claimed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | claimed |
| EP-1984325-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-29 | — | — | EP | claimed |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY (US) | 2008-02-21 | — | — | US | claimed |
| WO-2007120379-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | WO | claimed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | claimed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | claimed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| JP-2006510736-A | — | — | 2006-03-30 | — | — | JP | claimed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| EP-4349331-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | Kyoto Pharmaceutical University (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117209558-A | Use of Mpro protein inhibitors in medicaments for the treatment of novel coronavirus infections | 北京大学深圳研究生院 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023145804-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2023-08-03 | — | — | WO | disclosed |
| WO-2022259993-A1 | PPARα TRANSCRIPTION ACTIVATOR AND PHARMACEUTICAL USE THEREOF | 国立大学法人大阪大学 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022255499-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | 学校法人京都薬科大学 | 2022-12-08 | — | — | WO | disclosed |
| US-11179471-B2 | Peptide for cytosolic delivery | KYOTO UNIVERSITY (JP) | 2021-11-23 | — | — | US | disclosed |
| WO-2021020462-A1 | INTRACELLULAR DELIVERY PEPTIDE | 国立大学法人京都大学 | 2021-02-04 | — | — | WO | disclosed |
| US-20200384111-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3725331-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-20200046840-A1 | PEPTIDE FOR CYTOSOLIC DELIVERY | KYOTO UNIVERSITY (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3604520-A1 | PEPTIDE FOR CYTOSOLIC DELIVERY | Kyoto University (JP) | 2020-02-05 | — | — | EP | disclosed |
| WO-2019078171-A1 | METHOD FOR CONCENTRATING OR SEPARATING POLYMER COMPOUND | 国立大学法人京都大学 | 2019-04-25 | — | — | WO | disclosed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-2308960-B1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | UNIV KYOTO (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2684468-A1 | SALTY TASTE ENHANCER | Ajinomoto Co., Inc. (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20140004243-A1 | SALTY TASTE ENHANCER | AJINOMOTO CO., INC. (JP) | 2014-01-02 | — | — | US | disclosed |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2611805-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | Takeda Pharmaceutical Company Limited (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-102869666-A | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC | 2013-01-09 | — | — | CN | disclosed |
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2460814-A1 | PEPTIDIC COMPOUND AND USE OF SAME | Keio University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122797-A1 | PEPTIDIC COMPOUND AND USE OF SAME | KEIO UNIVERSITY (JP) | 2012-05-17 | — | — | US | disclosed |
| CN-102388044-A | Heterocyclic inhibitors of histamine receptors for the treatment of diseases | KALYPSYS INC | 2012-03-21 | — | — | CN | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2012029991-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| CN-102161643-A | Heterocyclic carboxylic acid derivative and application as endothelin receptor antagonist thereof | UNIV CHINA PHARMA | 2011-08-24 | — | — | CN | disclosed |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | KYOTO UNIVERSITY (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2318307-A2 | HETEROGENEOUS HYDROGEN-CATALYST REACTOR | Blacklight Power, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2308960-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | Kyoto University (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305219-A1 | Pharmaceutical preparations coated with a copolyvidone-containing coating | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7880012-B2 | e.g. 3-[2-(3-Isopropoxy-5-phenoxy-benzoylamino)-thiazol-5-yl-sulfanyl]-propionic acid methyl ester; metabolic disorder, blood glucose lowering, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, Polycystic Ovarian Syndrome, type I and type II diabetes, dyslipidemia, hyperlipidemia etc. | TRANSTECH PHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | VTVX HOLDINGS I LLC | 2010-12-30 | — | — | US | disclosed |
| EP-2019823-B1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100183604-A1 | PREVENTIVE/REMEDY FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| US-7741520-B2 | Sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2163258-A1 | PREVENTIVE/REMEDY FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2010014684-A2 | HETEROGENEOUS HYDROGEN-CATALYST REACTOR | BLACKLIGHT POWER, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, LLC | 2009-07-09 | — | — | US | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| EP-2019823-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-2019824-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-1984325-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1953147-A1 | HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF | Japan Tobacco, Inc. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007120379-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070093535-A1 | Vinyl phenyl derivatives as GLK activators | ASTRAZENECA AB | 2007-04-26 | — | — | US | disclosed |
| US-7199140-B2 | Vinyl phenyl derivatives as GLK activators | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7125999-B2 | Process for producing organotitanium compound and process for addition reaction | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050228020-A1 | Beta secretase inhibitors | MIYAMOTO MASAOMI | 2005-10-13 | — | — | US | disclosed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-6884806-B2 | Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050085553-A1 | Remedies for mild recognition deflict | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| US-20050054715-A1 | Vinyl phenyl derivatives as glk activators | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1459764-A1 | REMEDIES FOR MILD RECOGNITION DEFLICT | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040167344-A1 | Process for producing organotitanium compound and process for addition reaction | FUMIE SATO | 2004-08-26 | — | — | US | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| CN-1520296-A | Amino nicotinate derivatives as glucokinase (GLK) modulators | — | 2004-08-11 | — | — | CN | disclosed |
| US-20040110743-A1 | -Secretase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-10 | — | — | US | disclosed |
| US-6743916-B2 | REACTING AN ACETYLENE COMPOUND IN THE PRESENCE OF A TITANIUM COMPOUND AND GRIGNARD REAGENT TO OBTAIN ORGANOTITANIUM COMPOUND | Sato, Fumie (JP) | 2004-06-01 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6586475-B1 | 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-0921116-B1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-20030096996-A1 | Process for producing organotitanium compound and process for addition reaction | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1283055-A1 | SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1283039-A1 | -SECRETASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6495548-B1 | SUCH AS 3-((2,2-DIMETHYL-1-OXOPROPYL)AMINO)-N-HYDROXY-1-(4-((2-METHYL-4 -QUINOLINYL)METHOXY)PHENYL)-2-OXO-3-PYRROLIDINE ACETAMIDE; PREVENTING UNCONTROLLED BREAKDOWN OF CONNECTIVE TISSUE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6455522-B1 | ANTIINFLAMMATORY AGENTS; AGGRECANASE AND TUMOR NECROSIS FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1165546-A2 | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-ALPHA, AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6329389-B1 | HETEROCYCLIC AMINES AND DERIVATIVES, SOMATOSTATIN AND ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1132376-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1070054-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000059285-A2 | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999052875-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-21 | — | — | WO | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5856334-A | ANTAGONIST FOR EOSINOPHILS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0773219-A1 | IMIDAZOQUINOLINE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| US-5403868-A | Capsaicin derivatives | SANDOZ LTD. (CH) | 1995-04-04 | — | — | US | disclosed |
| US-5403868-A | Capsaicin derivatives | SANDOZ LTD. (CH) | 1995-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (34 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | DPP4 967/4885KMT2A 3303/4885FOLH1 640/4885 |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | DPP4 977/4885KMT2A 3435/4885FOLH1 1883/4885 |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | DPP4 967/4885KMT2A 3303/4885FOLH1 640/4885 |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | DPP4 967/4885KMT2A 3303/4885FOLH1 640/4885 |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | BACE1, BACE2, APP | DPP4 228/4885KMT2A 2224/4885FOLH1 902/4885 |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | DPP4 1286/4885KMT2A 1979/4885FOLH1 3055/4885 |
| US-20040167344-A1 | Process for producing organotitanium compound and process for addition reaction | ZYX, H1-4, GRIA4 | DPP4 1777/4885KMT2A 206/4885FOLH1 4863/4885 |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | DPP4 171/4885KMT2A 3067/4885FOLH1 535/4885 |
| US-20120122797-A1 | PEPTIDIC COMPOUND AND USE OF SAME | ASNS, ANPEP, NGLY1 | DPP4 1644/4885KMT2A 2201/4885FOLH1 765/4885 |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | DPP4 99/4885KMT2A 1445/4885FOLH1 1143/4885 |
| US-20050085553-A1 | Remedies for mild recognition deflict | ACHE, CHAT, PSEN1 | DPP4 422/4885KMT2A 3711/4885FOLH1 1194/4885 |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, HK2 | DPP4 102/4885KMT2A 1203/4885FOLH1 1654/4885 |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | EPCAM, HDGF, DSC1 | DPP4 2316/4885KMT2A 3210/4885FOLH1 1283/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | DPP4 1286/4885KMT2A 1979/4885FOLH1 3055/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | DPP4 967/4885KMT2A 3303/4885FOLH1 640/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | DPP4 145/4885KMT2A 4498/4885FOLH1 1599/4885 |
| US-20100183604-A1 | PREVENTIVE/REMEDY FOR CANCER | CFL1, LIMK1, LIMK2 | DPP4 4560/4885KMT2A 1729/4885FOLH1 927/4885 |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | CYP19A1, AR, SULT2A1 | DPP4 4526/4885KMT2A 190/4885FOLH1 2873/4885 |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | DPP4 117/4885KMT2A 3459/4885FOLH1 1378/4885 |
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | APP, BDNF, BACE1 | DPP4 3014/4885KMT2A 4333/4885FOLH1 3593/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | DPP4 99/4885KMT2A 1445/4885FOLH1 1143/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | DPP4 145/4885KMT2A 4498/4885FOLH1 1599/4885 |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | ROS1, JAK2, ERBB2 | DPP4 3882/4885KMT2A 382/4885FOLH1 3524/4885 |
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | DPP4 3504/4885KMT2A 4617/4885FOLH1 3218/4885 |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | DPP4 171/4885KMT2A 3067/4885FOLH1 535/4885 |
| US-20050228020-A1 | Beta secretase inhibitors | BACE1, BACE2, APP | DPP4 2095/4885KMT2A 2742/4885FOLH1 1617/4885 |
| US-20050054715-A1 | Vinyl phenyl derivatives as glk activators | GCK, GCKR, GK | DPP4 190/4885KMT2A 1295/4885FOLH1 1779/4885 |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | DPP4 3796/4885KMT2A 300/4885FOLH1 3329/4885 |
| US-20030096996-A1 | Process for producing organotitanium compound and process for addition reaction | ZYX, H1-4, GRIA4 | DPP4 1777/4885KMT2A 206/4885FOLH1 4863/4885 |
| US-20070093535-A1 | Vinyl phenyl derivatives as GLK activators | GCK, GCKR, GK | DPP4 186/4885KMT2A 1288/4885FOLH1 1763/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | DPP4 977/4885KMT2A 3435/4885FOLH1 1883/4885 |
| US-20200384111-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | CHRM1, SLC67A1, NPSR1 | DPP4 4446/4885KMT2A 4100/4885FOLH1 2049/4885 |
| US-20040110743-A1 | -Secretase inhibitors | BACE1, BACE2, PSEN1 | DPP4 2016/4885KMT2A 2333/4885FOLH1 1161/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | DPP4 977/4885KMT2A 3435/4885FOLH1 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.